Polycystic Ovary Syndrome Root Causes: Hyperandrogenism, Insulin Resistance, and LH Excess

Written by Adam Maggio | Medically reviewed by Dr. Sarah Chen, PharmD, BCPS

Polycystic Ovary Syndrome (PCOS) is driven by a complex interplay of hyperandrogenism, insulin resistance, and elevated luteinizing hormone (LH) levels, forming a vicious cycle that impacts reproductive and metabolic health.

Polycystic Ovary Syndrome (PCOS) is a common and complex endocrine disorder affecting 5-10% of women of reproductive age. It is a leading cause of anovulatory infertility, hirsutism, and metabolic dysfunction. The syndrome is characterized by a constellation of signs and symptoms, but its underlying pathophysiology is often described as a vicious cycle involving three key interconnected factors: hyperandrogenism, insulin resistance, and elevated luteinizing hormone (LH) levels. Understanding these root causes is crucial for effective diagnosis and management.

Hyperandrogenism: The Central Feature

Hyperandrogenism, defined as excessive androgen production or action, is a hallmark of PCOS and is present in 60-80% of affected women [1]. It manifests clinically as hirsutism (excessive hair growth in a male-like pattern), acne, and androgenic alopecia (female pattern hair loss). Biochemically, it is characterized by elevated circulating levels of testosterone (total and free), androstenedione, and dehydroepiandrosterone sulfate (DHEAS).

Ovarian Androgen Production: The primary source of excess androgens in PCOS is the ovaries, specifically the theca cells, which are hyper-responsive to LH stimulation. This leads to increased synthesis of androstenedione and testosterone [2].

Adrenal Androgen Production: In some women with PCOS, there may also be an increased adrenal androgen production, contributing to the overall hyperandrogenic state.

Reduced Sex Hormone-Binding Globulin (SHBG): Insulin resistance, a common feature of PCOS, reduces hepatic production of SHBG. SHBG binds to androgens, making them biologically inactive. A reduction in SHBG therefore increases the bioavailability of free (active) androgens, exacerbating the clinical manifestations of hyperandrogenism [3].

Insulin Resistance: The Metabolic Driver

Insulin resistance, defined as a diminished response of target tissues (muscle, liver, adipose tissue) to insulin, is present in 50-80% of women with PCOS, irrespective of obesity [4]. It plays a pivotal role in driving hyperandrogenism and is a major contributor to the metabolic complications of PCOS.

Compensatory Hyperinsulinemia: To overcome insulin resistance, the pancreatic beta cells produce excessive amounts of insulin, leading to hyperinsulinemia.

Ovarian Stimulation: Hyperinsulinemia directly stimulates ovarian theca cells to produce androgens, independent of LH. Insulin acts synergistically with LH to enhance androgen synthesis [5].

Reduced SHBG Synthesis: As mentioned, hyperinsulinemia suppresses hepatic SHBG production, further increasing free androgen levels.

Metabolic Consequences: Insulin resistance and compensatory hyperinsulinemia contribute to central obesity, dyslipidemia, impaired glucose tolerance, and an increased risk of type 2 diabetes and cardiovascular disease in women with PCOS [6].

LH Excess and Gonadotropin Dysregulation

Many women with PCOS exhibit a characteristic pattern of gonadotropin secretion: elevated luteinizing hormone (LH) levels relative to follicle-stimulating hormone (FSH), leading to an increased LH:FSH ratio. This dysregulation is thought to be driven by altered hypothalamic-pituitary feedback mechanisms, possibly influenced by hyperandrogenemia and insulin resistance [7].

Ovarian Theca Cell Hyperstimulation: Elevated LH directly stimulates the ovarian theca cells to produce excess androgens, as described above. This contributes to the follicular arrest and anovulation characteristic of PCOS, as the follicles fail to mature properly in the absence of adequate FSH stimulation.

Impaired Follicular Development: The relative deficiency of FSH, coupled with the androgen-rich microenvironment within the ovary, impairs the normal development and selection of a dominant follicle, leading to the characteristic 'polycystic' morphology of the ovaries (multiple small follicles arrested at an early stage of development) [8].

The Vicious Cycle

These three factors are not isolated but are intricately linked in a self-perpetuating cycle:

Insulin resistance leads to compensatory hyperinsulinemia.

Hyperinsulinemia stimulates ovarian androgen production and suppresses SHBG, leading to hyperandrogenism.

Hyperandrogenism, in turn, can exacerbate insulin resistance and alter hypothalamic-pituitary function, leading to increased LH pulsatility and LH excess.

LH excess further stimulates ovarian androgen production, perpetuating the cycle.

Clinical Implications for Management

Understanding this interconnected pathophysiology is critical for developing comprehensive management strategies for PCOS, which often involve targeting multiple aspects of the syndrome:

Lifestyle Modification: Diet and exercise are foundational, aiming to improve insulin sensitivity and reduce weight.

Insulin Sensitizers: Medications like metformin can improve insulin sensitivity, thereby reducing hyperinsulinemia and subsequently androgen levels.

Anti-Androgens: Medications such as spironolactone or oral contraceptives can directly address hyperandrogenism and its clinical manifestations.

Ovulation Induction: For infertility, treatments like clomiphene citrate or letrozole aim to restore normal follicular development and ovulation.

Conclusion

Polycystic Ovary Syndrome is a complex endocrine disorder rooted in a dysfunctional interplay of hyperandrogenism, insulin resistance, and LH excess. These three factors create a reinforcing cycle that drives the reproductive and metabolic abnormalities seen in PCOS. A comprehensive understanding of these root causes is essential for clinicians to provide effective, individualized management strategies that address both the symptoms and the underlying pathophysiology of this pervasive condition.